Medacta Group SA: directors' dealings · Switzerland · SIX SER

About Medacta Group SA

Medacta Group SA is a Swiss medical-device company focused on orthopaedics and spine surgery, listed on the SIX Swiss Exchange (SMI/SPI) under the ticker MOVE. Headquartered in Castel San Pietro, Switzerland, the company was founded in 1999 by Dr. Alberto Siccardi, an orthopaedic patient whose personal experience shaped a mission centered on surgical innovation, surgeon education, and better patient outcomes. Since its IPO in 2019, Medacta has developed into an international reference in implants and surgical solutions for hip, knee, shoulder, spine, and, more recently, sports medicine. The group operates in more than 70 countries and combines product development, medical education, and geographic commercial expansion as the core of its growth model. Medacta’s portfolio is anchored in hip and knee replacement, complemented by shoulder systems, spine solutions, and a growing Sports Medicine business. A key strategic step in 2025 was the acquisition of Parcus Medical, a specialist in sports medicine and arthroscopy, which strengthened Medacta’s offering, broadened its access to global distribution channels, and increased its footprint in the U.S. ambulatory surgery center market. Competitively, Medacta differentiates itself through a patient-centered approach, minimally invasive techniques, personalized implants, and significant investment in surgeon training through the M.O.R.E. institute and related scientific programs. Recent product and commercial developments include the international rollout of GMK SpheriKA in knee replacement, the expansion of the MyImplant platform for complex hip reconstruction, and new fixation and shoulder-related solutions launched across 2025 and 2026. From a market perspective, Medacta delivered strong 2025 revenue growth, improved adjusted EBITDA margins, and higher net profit, underscoring its ability to grow above the broader orthopaedic market. For investors, the company offers a growth profile with meaningful international exposure, a differentiated innovation platform, and a disciplined operating model in a healthcare segment where clinical adoption, surgeon loyalty, and pipeline depth are critical to long-term value creation.